Costs of oxygen therapy for interstitial lung disease and chronic obstructive pulmonary disease: A retrospective study from a universal healthcare system

The “silent threat” of nocturnal hypoxia remains unresolved for patients with fibrotic interstitial lung diseases

“…The use of oxygen may hinder travel by aeroplane and could potentially lead to a decrease in outdoor activities due to concerns about others’ attention. It is also necessary to consider whether the cost-effectiveness is adequate [ 22 ]. Even if future clinical studies show the benefits of long-duration oxygen therapy, physicians should alert patients to these effects and help them decide on the best way to meet their needs.…”